MedTrace Logo

Safety of Diamyd® in Patients With LADA (Latent Autoimmune Diabetes in Adult)

NCT00456027 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 160

Last updated 2011-06-10

No results posted yet for this study

Summary

This is a study to investigate the safety of 20ug Diamyd® (rhGAD65 formulated in Alhydrogel®), administered subcutaneously four weeks apart in patients with Latent Autoimmune Diabetes in Adult (LADA).

Conditions

  • Latent Autoimmune Diabetes in Adult (LADA)

Interventions

DRUG

rhGAD65 formulated in Alhydrogel® (Diamyd®)

20 micrograms of rhGAD65 formulated in Alhydrogel® administered subcutaneously twice 4 weeks apart

Sponsors & Collaborators

  • Diamyd Therapeutics AB

    lead INDUSTRY

Principal Investigators

  • Carl-David Agardh, MD, phD · University Hospital MAS, Malmö, Sweden

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
30 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-12-31
Primary Completion
2008-03-31
Completion
2008-04-30

Countries

  • Sweden

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00456027 on ClinicalTrials.gov